Pfizer’s sharp drop in Covid vaccine revenues and rising short interest have put big pharma under a harsh spotlight, which pulls the wider biotechnology sector into focus. When a heavyweight like Pfizer faces questions over debt, dividends and pipeline depth, other large biotech stocks can suddenly look more interesting or more exposed. This article walks through 3 stocks from our Biotechnology Sector screener that appear positively linked to this news backdrop and explains why each might deserve a closer look now.

The three biotech stocks below are only a starting sample, and the full screen surfaced 8 more large cap companies in the biotechnology sector with equally compelling narratives that are not covered here. To identify and analyze the highest conviction setups across this group, head straight to the Biotechnology Sector screener.

Royalty Pharma (RPRX)

Royalty Pharma is a specialist investor in drug royalties, effectively financing biopharma research in return for a share of future sales on around 35 approved therapies and 20 pipeline drugs across areas like rare disease, oncology and neuroscience. It generates about US$2.5b in revenue from acquiring biopharmaceutical royalties, all currently reported from the United States. The company sits in large cap territory with a market value of roughly US$32.6b.

Royalty Pharma gives you exposure to a wide slice of biotech at once, which may be particularly relevant while Pfizer manages falling Covid revenues and heavy debt. Instead of focusing on a single drug, this is a portfolio of royalties tied to multiple therapies, supported by recent deals such as the Neurimmune cliramitug royalty and Q2 2026 results that exceeded revenue and EPS expectations. The flip side is meaningful leverage, margin pressure and executive pay and insider selling trends that some investors may find uncomfortable. For readers who want a more diversified way to access biotech cash flows while keeping a close eye on funding risk and concentration in a few large assets, Royalty Pharma is a stock worth understanding more deeply.

Royalty Pharma’s wide royalty portfolio could be masking a very different risk reward profile than a single biotech stock. Scan the 2 key rewards and 3 important warning signs that might flip how you see its leverage and cash flows.

Build your own biotech royalty shortlist

Royalty Pharma and the two other biotech stocks in this article all came from the same set of filters, which you can easily adapt to your own style. Use our flexible Screener to mix metrics like cash flows, balance sheet strength and risks, or jump straight into our curated Investing Ideas for ready made stock shortlists.

TG Therapeutics (TGTX)

TG Therapeutics is a commercial stage biotech company that develops and sells treatments for B cell mediated diseases, led by BRIUMVI for adults with relapsing forms of multiple sclerosis. The business currently reports about US$800 million in revenue from its biotechnology operations and has a market value of roughly US$7.1b.

Investors are paying attention to TG Therapeutics because BRIUMVI is already building a real commercial footprint while a subcutaneous version could open a larger slice of the multiple sclerosis market that favors self administered therapies. The company is also highlighting potential new uses in conditions such as myasthenia gravis and treatment resistant schizophrenia, which together could extend the life of its core franchise if the data and regulators cooperate. At the same time, heavy reliance on a single drug, high debt and management’s richer pay packet mean investors may want to weigh the concentration and governance risk carefully rather than treating the stock as a simple Covid recovery trade.

TG Therapeutics is riding a single blockbuster story in BRIUMVI, yet the bigger question is where growth goes next. Scan the analyst forecasts for TG Therapeutics to see what expectations might be missing about its next chapters

ADMA Biologics (ADMA)

ADMA Biologics develops, manufactures and sells plasma derived therapies that treat immune deficiencies and infectious diseases, including BIVIGAM, ASCENIV and Nabi HB. The company also runs plasma collection centers that feed its manufacturing operations and sells finished products through wholesalers, specialty pharmacies and other providers. ADMA Biologics has a market value of about US$2.2b.

ADMA Biologics sits in a corner of biotech that looks very different to Pfizer’s high profile vaccine swings. Its focus on immune globulin products and plasma collection has produced a 33% net margin and a 41.4% ROE, and Q2 2026 results showed higher sales, wider gross margins and solid cash generation alongside a planned US$200m plus buyback. At the same time, heavy reliance on a narrow product set, legal overhang from a class action and tough competition from larger plasma players mean the story is not risk free. For investors who want exposure to biotech innovation without direct Covid or pricing pressure, ADMA Biologics is a business that could be worth a deeper look.

ADMA Biologics pairs a 33% net margin with a 41.4% ROE that many investors may not have fully factored in yet. Walk through the story behind those numbers in the analysis report for ADMA Biologics

Seeking Alternatives Before The Crowd

Fresh ideas do not stay under the radar for long. Stocks can move fast once momentum builds, and the most attractive entry points can be caught early. Consider researching opportunities before they become widely followed.

• Identify companies that may be quietly building strength before momentum headlines arrive by scanning the list of solid balance sheet and fundamentals (49 results).
• Explore the next wave of AI demand by tracking cash generative specialists through the 69 profitable AI stocks that aren't just burning cash.
• Assess long term infrastructure themes while they may still be priced as afterthoughts with the 36 power grid technology and infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.